<p>Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of <em>The Lancet Neurology.</em></p>

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

In conversation with... Alexandra Durr

The Lancet Neurology is a monthly journal, renowned for the publication of high-quality peer-reviewed research, reviews, and analysis from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue, with occasional interviews with an author of a key article.

Share In conversation with... Alexandra Durr

Sign up to save your podcasts

In conversation with... Alexandra Durr

In conversation with... Alexandra Durr